1 / 17

NC BioStart

NC BioStart. Translation through Commercialization. Who we are. Dr. Richard Boucher Executive Director Don Rose, Ph.D. Director Ilona Ori Program Assistant Justin Brown, Ph.D. Visiting Scholar, Entrepreneurship Entrepreneurs-in-Residence Tom Mercolino, Ph.D Joel Shaffer, Ph.D.

alban
Télécharger la présentation

NC BioStart

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NC BioStart Translation through Commercialization

  2. Who we are • Dr. Richard Boucher Executive Director • Don Rose, Ph.D. Director • Ilona Ori Program Assistant • Justin Brown, Ph.D. Visiting Scholar, Entrepreneurship • Entrepreneurs-in-Residence • Tom Mercolino, Ph.D • Joel Shaffer, Ph.D. • Perry Genova, Ph.D.

  3. Rationale • Value of University Startups • Translation through Commercialization • Faculty Recruitment and Retention • Increase Value of University Assets • Economic Development • Build on current efforts at UNC to foster startups • Launching the Venture (KFBS) • Carolina Express License (OTD)

  4. Program Overview • Mission • Facilitate and accelerate University startups • Scope • Life science (drugs, devices, diagnostics, tools) • Breadth • Today: UNC-CH campus • Future: All state-supported campuses • Location and Funding • NC Translational and Clinical Sciences Institute • Home of NIH CTSA Grant (Etta Pisano, PI)

  5. DRAFT NC BioStart

  6. Tom Mercolino PhD (UNC’88) – Microbiology & Immunology BS – Chemistry Registered Patent Agent >25 Years in Pharma & Diagnostics R&D Management Becton Dickinson Johnson & Johnson Entrepreneur Founder & CEO of CertiRx 7

  7. Tom Mercolino Representative Client Companies Rheomics - early College of Arts& Sciences (Prof. Physics Department) Re-focused technology platform to high-value applications Hepa Ca Dx - nascent UNC Gillings School of Global Public Health (PhD Student) organizing clinical proof of principle X-In8 - established School of Medicine (Prof. surgery) Id and resolution of potential patent issue in partnership with OTD 8

  8. Joel Shaffer Entrepreneur in Residence for Therapeutics 9

  9. Resume • 5 yrs at American Critical Care (DuPont) • 17 yrs at Glaxo (GW, GSK) • Business Development for Metabolic Diseases • Head of Pharmacology • High-throughput screening • Preclinical Project leader • R&D in Cardiovascular, Oncology, Urology, Metabolic Diseases 10

  10. Entrepreneur-in-Residence at UNC May 2009 • Advising 7 UNC clients • Enci Therapeutics • Hibernaid • Novolipid • Synereca • (Scott Singleton, Ph.D. Med. Chem. natural prod.) • G-zero • (Ned Sharpless, M.D. Medicine, genetics) • Matt Redinbo, Ph.D. Chemistry, structural chemistry • Mark Zylka, Ph.D. Cell & Molecular Physiology 11

  11. Enci Therapeutics • Cam Patterson, M.D. and Nancy DeMore, M.D. • Discovery of new angiogenesis factor (SFRP2) • Developed a mouse mAb • The antibody blunts tumor growth • How does this target compare to VEGF? • How do we make a human mAb for clinical testing? 12

  12. Hibernaid • Larry Katz, M.D. • Has studied hypothermia mechanisms for years • Ice baths improve outcome for pts with cardiac arrest • Discovered that certain agents used in combination (unexpectedly) lower the body’s temperature set point • Determined a fixed combination of agents will: • Lower temp by 4-5 oC • Increase survival after acute cardiac arrest in rats and pigs • Improve CNS performance post injury • Will this benefit patients suffering from reperfusion injury? 13

  13. Novolipid • Mike Hackett and Deepak Gopalakrishna • Graduate students, Pharmacy and Molecular Biology • Discovered that they could covalently attach cytotoxic chemotherapeutic drugs to small lipids which have high affinity to albumin • Longer half-life • Less systemic toxicity of drug • No need for toxic solvents • Better tumor penetration • Will this show superior effects in animals and humans? 14

  14. Perry Genova MS, PhD Biomedical Engineering BS EE, BME Serial entrepreneur (IEP, Quill, Oncoscope) Global VP – GSK (MDI business – France) VP – Kos Pharmaceuticals Inhaled product development including insulin Worked for Adrian Adams (CEO – Inspire) 15

  15. Melanie Joy (UNC) and Marian McCord (NCSU) Addresses large unmet need (160,000 patients) Remove excess phosphate from blood during dialysis High phosphate associated with morbidity and mortality Technology combines phosphate adsorption chemistry with filtration science Improved compliance, no side effects TraCS grant supported feasibility work TAM = 25M devices, $2.5B market Katharos – Improving care for dialysis patients

  16. Contact Information • Don Rose • Director, NC BioStart • donrose@email.unc.edu • www.ncbiostart.com • Ilona Ori • Program Assistant • ilona_ori@med.unc.edu • 919-843-3304 • Upcoming Events • Commercialization Webinar • “Incorporation and Founder’s Stock” • Ken Eheman and Anthony Williams, WRYP • March 15th, 12 – 1 pm • Emerging Company Showcase • April 12th, 6 pm, Kenan-Flagler Business School

More Related